HomeCompareMDT vs MCO

MDT vs MCO: Dividend Comparison 2026

MDT yields 3.31% · MCO yields 0.89%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCO wins by $152.9K in total portfolio value· pulled ahead in Year 6
10 years
MDT
MDT
● Live price
3.31%
Share price
$85.74
Annual div
$2.84
5Y div CAGR
29.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.3K
Annual income
$9,789.15
Full MDT calculator →
MCO
MCO
● Live price
0.89%
Share price
$432.05
Annual div
$3.85
5Y div CAGR
74.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207.2K
Annual income
$113,279.94
Full MCO calculator →

Portfolio growth — MDT vs MCO

📍 MCO pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDTMCO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDT + MCO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDT pays
MCO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDT
Annual income on $10K today (after 15% tax)
$281.55/yr
After 10yr DRIP, annual income (after tax)
$8,320.78/yr
MCO
Annual income on $10K today (after 15% tax)
$75.74/yr
After 10yr DRIP, annual income (after tax)
$96,287.95/yr
At 15% tax rate, MCO beats the other by $87,967.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDT + MCO for your $10,000?

MDT: 50%MCO: 50%
100% MCO50/50100% MDT
Portfolio after 10yr
$130.7K
Annual income
$61,534.55/yr
Blended yield
47.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MDT right now

MDT
Analyst Ratings
1
Strong
26
Buy
22
Hold
Consensus: Buy
Price Target
$111.45
+30.0% upside vs current
Range: $100.00 — $120.00
Altman Z
2.9
Piotroski
7/9
MCO
Analyst Ratings
18
Buy
13
Hold
1
Sell
Consensus: Buy
Price Target
$543.08
+25.7% upside vs current
Range: $480.00 — $620.00
Altman Z
5.3
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDT buys
0
MCO buys
0
No recent congressional trades found for MDT or MCO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDTMCO
Forward yield3.31%0.89%
Annual dividend / share$2.84$3.85
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR29.3%74.8%
Portfolio after 10y$54.3K$207.2K
Annual income after 10y$9,789.15$113,279.94
Total dividends collected$29.9K$178.5K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusBuyBuy
Analyst price target$111.45$543.08

Year-by-year: MDT vs MCO ($10,000, DRIP)

YearMDT PortfolioMDT Income/yrMCO PortfolioMCO Income/yrGap
1$11,128$428.29$10,856$155.76+$272.00MDT
2$12,483$575.94$11,892$276.24+$591.00MDT
3$14,138$780.71$13,219$494.35+$919.00MDT
4$16,196$1,068.46$15,042$897.70+$1.2KMDT
5$18,809$1,479.09$17,763$1,668.77+$1.0KMDT
6← crossover$22,201$2,075.70$22,226$3,219.45$25.00MCO
7$26,716$2,960.69$30,363$6,580.83$3.6KMCO
8$32,891$4,305.30$47,175$14,686.41$14.3KMCO
9$41,599$6,405.16$87,754$37,276.83$46.2KMCO
10$54,300$9,789.15$207,177$113,279.94$152.9KMCO

MDT vs MCO: Complete Analysis 2026

MDTHealthcare

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Full MDT Calculator →

MCOFinancials

Moody's Corporation operates as an integrated risk assessment firm worldwide. It operates in two segments, Moody's Investors Service and Moody's Analytics. The Moody's Investors Service segment publishes credit ratings and provides assessment services on various debt obligations, programs and facilities, and entities that issue such obligations, such as various corporate, financial institution, and governmental obligations, as well as and structured finance securities. This segment provides ratings in approximately 140 countries. Its ratings are disseminated through press releases to the public through electronic media, including the internet and real-time information systems used by securities traders and investors. This segment has rated approximately 5,000 non-financial corporates; 3,600 financial institutions; 16,000 public finance issuers; 145 sovereigns; 47 supranational institutions; 459 sub-sovereigns; and 1,000 infrastructure and project finance issuers, as well as 9,100 structured finance deals. The Moody's Analytics segment develops a range of products and services that support the risk management activities of institutional participants in financial markets; and offers subscription based research, data, and analytical products comprising credit ratings, credit research, quantitative credit scores and other analytical tools, economic research and forecasts, business intelligence and company information products, commercial real estate data and analytical tools, and on-line and classroom-based training services, as well as credentialing and certification services. It also offers offshore analytical and research services with learning solutions and certification programs; and software solutions, as well as related risk management services. The company was formerly known as Dun and Bradstreet Company and changed its name to Moody's Corporation in September 2000. Moody's Corporation was founded in 1900 and is headquartered in New York, New York.

Full MCO Calculator →
📬

Get this MDT vs MCO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDT vs SCHDMDT vs JEPIMDT vs OMDT vs KOMDT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.